comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 12:48:08 - browse：899

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Humans aren't the only ones with an imagination. Rats have it too

WSS

All of Us, NIH's precision medicine initiative, gets a big boost

Novo Nordisk touts Wegovy study, but still struggling with supply

All of Us, NIH's precision medicine initiative, gets a big boost

Prime Medicine says its gene editing passes test in monkeys

Gene therapy’s promise and the high cost of hope

Schizophrenia gene found to be linked to cells' energy dysfunction

focus

comprehensive

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The health care issue Democrats can’t solve: hospital reform

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Kidney transplant patients stopped immunosuppressants in trial

23andMe had bad news about my health. I wish a person had delivered it

Health AI: on the border between health care and tech

Novavax promises a turnaround & Lilly roils the obesity market

Patients, digital health players weigh in on FTC's data privacy plan

Bright Health sells Medicare Advantage business to Molina

Dozens dead from Maui wildfires: What we know about the victims

explore

Timeline: How the deadly wildfires took over Maui day by day

All of Us, NIH's precision medicine initiative, gets a big boost

The health care issue Democrats can’t solve: hospital reform

Maui wildfire now ranks as the fifth

Timeline: How the deadly wildfires took over Maui day by day

Dozens dead from Maui wildfires: What we know about the victims

explore

knowledge

Wikipedia

focus